Home/Filings/4/0001209191-21-068455
4//SEC Filing

Klein Lawrence Otto 4

Accession 0001209191-21-068455

CIK 0001674416other

Filed

Dec 6, 7:00 PM ET

Accepted

Dec 7, 8:00 PM ET

Size

9.2 KB

Accession

0001209191-21-068455

Insider Transaction Report

Form 4
Period: 2021-12-03
Klein Lawrence Otto
Chief Business Officer
Transactions
  • Exercise/Conversion

    Common Shares

    2021-12-03+26,66733,510 total
  • Tax Payment

    Common Shares

    2021-12-06$69.17/sh11,185$773,66622,325 total
  • Exercise/Conversion

    Restricted Stock Units

    2021-12-03+26,66713,333 total
    Common Shares (26,667 underlying)
Footnotes (3)
  • [F1]The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • [F3]On December 3, 2019, the reporting person was granted 40,000 restricted stock units. On December 3, 2021, 26,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Issuer

CRISPR Therapeutics AG

CIK 0001674416

Entity typeother

Related Parties

1
  • filerCIK 0001762583

Filing Metadata

Form type
4
Filed
Dec 6, 7:00 PM ET
Accepted
Dec 7, 8:00 PM ET
Size
9.2 KB